
Opinion|Videos|April 3, 2025
Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health
Panelists discuss how optimizing antibody-drug conjugate (ADC) therapy in patients with metastatic breast cancer (mBC) requires interdisciplinary care, including oncologists, pharmacists, and nurses. Adherence barriers such as cost, access, and insurance are addressed via financial and social support.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- What interdisciplinary approaches to care can help optimize ADC therapy outcomes in patients with mBC?
- Do patients receiving ADC therapy at your practice experience adherence barriers due to social determinants of health, treatment costs, accessibility, or insurance coverage?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
2
Higher Ultra-Processed Food Intake Linked to Increased Prediabetes Risk in Young Adults
3
Study Finds Similar Outcomes Between hMPV and RSV Hospitalizations
4
Pharmacist Spotlight: Amir Masood, PharmD
5

















































































































































































































